Cysteamine for Asthma

  • STATUS
    Recruiting
  • participants needed
    50
  • sponsor
    Children's Hospital Medical Center, Cincinnati
Updated on 19 February 2024
corticosteroids
rhinitis
skin prick
allergen
eosinophil count
prick skin
pulmonary function test
skin prick test

Summary

The purpose of this study is to see if a medicine called Cysteamine, given along with standard asthma care, will improve asthma symptoms and lung function.

Description

Asthma affects 25.7 million people in the US. Many people report symptoms despite taking high-doses of inhaled asthma medications. This difficult-to-treat group accounts for more than 50% of asthma related healthcare visits and hospitalizations. The purpose of this study is to see if a medicine called Cysteamine, given along with standard asthma care, will improve asthma symptoms and lung function.
This study is a double-blind, placebo-controlled, randomized trial of cysteamine. A placebo arm will be included to determine the comparative effectiveness of cysteamine in this population. Eligible participants will be assessed 1, 4 and 8 weeks post randomization and followed for an additional 4 weeks post treatment.
In order to enroll in this study, participants must be between the ages of 18-45 and have uncontrolled asthma.
This study will include 4 visits and weekly phone calls, and will be in the study for 3-4 months.
During the treatment period, participants will be placed in one of two treatment groups:
  • Cysteamine
  • Placebo
Participants will not be able to choose which group they are assigned. This assignment is random and by chance, much like flipping a coin. Participants will not know if they are receiving Cysteamine or placebo. Investigators will compare the study results between the participants of each group.

Details
Condition Asthma, Asthma, Asthma (Pediatric), Allergies & Asthma, Asthma (Pediatric), Allergies & Asthma
Age 18-45 years
Treatment Cysteamine Bitartrate, Placebo Oral Tablet
Clinical Study IdentifierNCT03883984
SponsorChildren's Hospital Medical Center, Cincinnati
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Male or female
Age 18 years and 45 years
Provision of written informed consent
Asthma currently treated with moderate-high doses of Inhaled Corticosteroids (ICS) per the National Asthma Education and Prevention Program (NAEPP) guidelines by self-report
Evidence of hypersensitivity to environmental allergens, with at least one of the following
Elevated serum IgE
Positive allergy skin prick testing to at least 1 allergen
Evidence of allergic rhinitis by physical exam or by medical history
Peripheral blood eosinophils 150 cells/l obtained at screening visit
Asthma Severity Score indicating Moderate to Severe Impairment based on EPR-3 classification guidelines
> 1 utilization for treatment of asthma exacerbation including prescription of oral or intravenous steroids (urgent care, emergency department visit, or hospitalization for asthma) in the past 12 months
Negative urine pregnancy test for females of child bearing potential and use of contraception throughout the study

Exclusion Criteria

Diagnosis of chronic lung disease other than asthma
Have received biologic therapy (e.g., anti-IgE, anti-IL-4, anti-IL-5) within 6 months of study entry
Diagnosis of chronic disease other than asthma requiring daily steroids or immunosuppressive agents
History of a heart attack or severe chronic heart disease
Current smoking or previous history within 1 year
Transplant patient
IBD, Crohn's
History of ulcer, gastric esophageal reflux (GERD) or chronic peptic ulcer disease
Pregnant or planning to become pregnant
Breastfeeding
History of severe allergic or anaphylactic reactions to medications
Grade 2-4 Abnormal Laboratory Results (hemoglobin, WBC, lymphocytes, platelets, sodium, potassium, glucose, BUN, creatinine, calcium, albumin, total protein, alkaline phosphate, AST, ALT, and bilirubin), see table 7.4.1.2a and 7.4.1.2b
Grade 3-4 Abnormal Eosinophils and Neutrophils, see table 7.4.1.2a
Evidence of papilledema, or history of pseudotumor cerebri
History of persistent headaches
Allergic reaction to cysteamine or penicillamine
Serious medical condition that, in the opinion of the Study Investigator, would interfere with the ability of the patient to complete the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 â€¢ 

Private

Reply by • • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.